subject area of
- BCR–ABL1 transcript doubling time as a predictor for treatment‐free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase Academic Article
- A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours Academic Article
- Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors Academic Article
- Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib Academic Article
- Esophageal gastrointestinal stromal tumor: report of 7 patients Academic Article
- Gender andBCR-ABLtranscript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia Academic Article
- Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study Academic Article
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin Academic Article
- Imatinib mesylate in children and adolescents with cancer Academic Article
- Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma Academic Article
- Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial Academic Article
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results Academic Article
- The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia Academic Article
- Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease Academic Article
- XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors Conference Paper